Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis

NCT00962741 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00962741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00962741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
January 31, 2013
Enrollment
127 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, juvenile idiopathic